GlassScriptPhysician profile
Kinsey Johnson
NPI 1962122762
$1,377.53
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $409 · 2024: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.47 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $146.51 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $146.47 | 2023-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $144.60 | 2023-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $113.73 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $108.69 | 2024 | Auvelity |
| Corium, LLC | $75.31 | 2024 | Azstarys |
| Tris Pharma INC | $48.85 | 2024 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $40.02 | 2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $39.17 | 2024 | Austedo Xr |
| Myriad Genetic Laboratories, INC. | $37.03 | 2024 | Genesight |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.48 | 2024 | |
| Lundbeck LLC | $22.08 | 2023 | Rexulti |
| Neuronetics, INC. | $16.12 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kinsey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.